Ranbaxy Talks Up De-risking Strategy To Offset Impact Of Toansa Site Ban
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy fielded a volley of questions during a fourth quarter earnings call on the impact of the latest ban imposed by FDA on its Toansa, India site. Contrary to general estimates, Ranbaxy clarified the impact of the ban will be very limited on its North American business.
You may also be interested in...
Thousands Of Jobs May Go At Novartis But Worker Headcount To Stay Flat
Novartis plans to support new product launches and other activities around the world by re-allocating up to 4,000 positions, in order to make productivity gains.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.